Author

Julie Weng

Observed name: J. Weng

Observed institutions: University of California, San Francisco, Genentech, University of Toronto, Hospital for Sick Children, University of California San Francisco Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center

ORCID: 0009-0000-7974-435X

Observed ORCID: 0009-0000-7974-435X

OpenAlex ID: A5111663550

The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer

2007 · Electron Kebebew, Julie Weng, et al. · Annals of Surgery · 481

Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine‐needle Aspiration Biopsy

2010 · Willieford Moses, Julie Weng, et al. · World Journal of Surgery · 184

PDF

MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy

2010 · Erin E. Patterson, Alisha K. Holloway, et al. · Cancer · 171

PDF

Prevalence, Clinicopathologic Features, and Somatic Genetic Mutation Profile in Familial Versus Sporadic Nonmedullary Thyroid Cancer

2010 · Willieford Moses, Julie Weng, et al. · Thyroid · 151

MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer

2011 · Menno R. Vriens, Julie Weng, et al. · Cancer · 142

PDF

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia

2013 · Shilpa Gandre-Babbe, Prasuna Paluru, et al. · Blood · 120

Clinical and molecular features of papillary thyroid cancer in adolescents and young adults

2010 · Menno R. Vriens, Willieford Moses, et al. · Cancer · 86

CRISPR whole-genome screening identifies new necroptosis regulators and RIPK1 alternative splicing

2018 · Marinella G. Callow, Colin Watanabe, et al. · Cell Death and Disease · 54

PDF

A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy

2010 · Aarti Mathur, Julie Weng, et al. · Surgery · 46

Candidate Diagnostic Markers and Tumor Suppressor Genes for Adrenocortical Carcinoma by Expression Profile of Genes on Chromosome 11q13

2008 · Gustavo G. Fernandez‐Ranvier, Julie Weng, et al. · World Journal of Surgery · 41

Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia

2013 · Severa Bunda, Michelle W. Kang, et al. · Cancer Research · 29

Multiple Genetic Alterations in Papillary Thyroid Cancer are Associated with Younger Age at Presentation

2009 · Willieford Moses, Julie Weng, et al. · Journal of Surgical Research · 28

Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAFV600E positive papillary thyroid cancers

2008 · Daniel T. Ruan, Robert S. Warren, et al. · Surgery · 25

CRISPR activation screens identify the SWI/SNF ATPases as suppressors of ferroptosis

2024 · Kamakoti P. Bhat, Jinchu Vijay, et al. · Cell Reports · 20

Germline variation of the melanocortin‐1 receptor does not explain shared risk for melanoma and thyroid cancer

2009 · Jürgen Bauer, Julie Weng, et al. · Experimental Dermatology · 5

Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model

2026 · Thijs J. Hagenbeek, Jason Zbieg, et al. · Nature Communications · 4

Data from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

2025 · Ashley V. DiMarco, Mirunalini Ravichandran, et al. · 1

Abstract 6849: RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy

2025 · Ashley DiMarco, Mirunalini Ravichandran, et al. · Cancer Research · 1

RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy

2024 · Danilo Maddalo, Ashley DiMarco, et al. · Research Square · 1

PDF

Supplementary Figure S4 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy